KN

Karthikeyan Narasingapuram Arumugam

Active Director Director DIN 10954884
DIN 10954884 First appointment Feb 2025 Primary industry Paper
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Feb 2025
Shareholding value β€’β€’β€’β€’ Premium profile

About Karthikeyan Narasingapuram Arumugam

Data last updated:

Karthikeyan Narasingapuram Arumugam is a Director at Genvicure Therapeutics Private Limited (since 2025). The company operates in Paper.

DIN 10954884
Primary Designation Director
Industry Paper
First Appointment 18 Feb 2025
Oldest Company Age 1 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director18 Feb 20252025Active

Board colleagues of Karthikeyan Narasingapuram Arumugam

Directorship timeline

Open interactive timeline →
Genvicure Therapeutics Private Limited
Premium access

Shareholding and investment profile for Karthikeyan Narasingapuram Arumugam

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Karthikeyan Narasingapuram Arumugam

Karthikeyan Narasingapuram Arumugam currently holds 1 directorship: Genvicure Therapeutics Private Limited (Director, since 18 Feb 2025).

Karthikeyan Narasingapuram Arumugam was first appointed on 18 Feb 2025 as Director at Genvicure Therapeutics Private Limited.

The current boards of Karthikeyan Narasingapuram Arumugam's companies include Mulchand Mangilal Darji (Genvicure Therapeutics Private Limited), Sateesh Chander Siddozu (Genvicure Therapeutics Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available